Facing mounting economic pressures and the exodus of foreign talent due to strict "COVID Zero" policies, China is launching a new charm offensive designed to lure multinational drug makers, which still play a key role driving innovation in the pharma, biotech and life science sectors in the country.
New policies aimed at improving the regulatory environment are intended to make such companies feel more welcomed in China and are possibly a response to
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?